These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30288313)

  • 1. HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates.
    Fotiou A; Kanavou E; Antaraki A; Richardson C; Terzidou M; Kokkevi A;
    Hepatol Med Policy; 2016; 1():9. PubMed ID: 30288313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India.
    Clipman SJ; Mehta SH; Srikrishnan AK; Zook KJ; Duggal P; Mohapatra S; Shanmugam S; Nandagopal P; Kumar MS; Ogburn E; Lucas GM; Latkin CA; Solomon SS
    Elife; 2021 Aug; 10():. PubMed ID: 34342266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India.
    Ray Saraswati L; Sarna A; Sebastian MP; Sharma V; Madan I; Thior I; Pulerwitz J; Tun W
    BMC Public Health; 2015 Jul; 15():726. PubMed ID: 26223866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
    Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
    BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of HIV/Hepatitis C Virus Co-Infection and Injection Risk Correlations in People Who Inject Drugs in Colombia: A Cross-Sectional Study Using Respondent Driven Sampling.
    Toro-Tobón D; Berbesi-Fernández D
    Subst Use Misuse; 2020; 55(3):414-423. PubMed ID: 31691646
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence of HIV, Hepatitis C and its related risk behaviours among women who inject drugs in the Kathmandu Valley, Nepal: a cross-sectional study.
    Damas J; Storm M; Pandey LR; Marrone G; Deuba K
    Ther Adv Infect Dis; 2021; 8():20499361211062107. PubMed ID: 34881024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.
    Zhang L; Celentano DD; Le Minh N; Latkin CA; Mehta SH; Frangakis C; Ha TV; Mo TT; Sripaipan T; Davis WW; Quan VM; Go VF
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):550-6. PubMed ID: 25769097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C Virus-HIV Coinfection in the United States Among People Who Inject Drugs: Data Needed for Ending Dual Epidemics.
    Moorman AC; Bixler D; Teshale EH; Hofmeister M; Roberts H; Chapin-Bardales J; Gupta N
    Public Health Rep; 2023 Jul; ():333549231181348. PubMed ID: 37480274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and hepatitis B and C co-infection among people who inject drugs in Zanzibar.
    Khatib A; Matiko E; Khalid F; Welty S; Ali A; Othman A; Haji S; Dahoma M; Rutherford G
    BMC Public Health; 2017 Nov; 17(1):917. PubMed ID: 29183287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: Findings from respondent-driven sampling surveys.
    Handanagic S; Bozicevic I; Civljak M; Dominkovic Z; Sevic S; Barbaric J; Nemeth Blazic T; Dakovic Rode O; Begovac J
    Int J Drug Policy; 2016 Jun; 32():57-63. PubMed ID: 27160504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study.
    Gountas I; Sypsa V; Papatheodoridis G; Paraskevis D; Kalamitsis G; Anagnostou O; Antaraki A; Fotiou A; Hatzakis A
    J Viral Hepat; 2019 Nov; 26(11):1311-1317. PubMed ID: 31322302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing risk environments for HIV among people who inject drugs from three cities in Northern Mexico.
    Ospina-Escobar A; Magis-Rodríguez C; Juárez F; Werb D; Bautista Arredondo S; Carreón R; Ramos ME; Strathdee S
    Harm Reduct J; 2018 May; 15(1):27. PubMed ID: 29776368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High burden of hepatitis C & HIV co-infection among people who inject drugs in Manipur, Northeast India.
    Kermode M; Nuken A; Medhi GK; Akoijam BS; Sharma HU; Mahanta J
    Indian J Med Res; 2016 Mar; 143(3):348-56. PubMed ID: 27241649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with HCV test uptake in heroin users entering substitution treatment in Greece.
    Anagnostou O; Fotiou A; Kanavou E; Antaraki A; Terzidou M; Richardson C; Kafetzopoulos E;
    HIV Med; 2018 Feb; 19 Suppl 1():34-39. PubMed ID: 29488704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
    Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
    Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study.
    Leprêtre A; Ba I; Lacombe K; Maynart M; Toufik A; Ndiaye O; Kane CT; Gozlan J; Tine J; Ndoye I; Raguin G; Girard PM
    J Int AIDS Soc; 2015; 18(1):19888. PubMed ID: 26004637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection.
    Lo Re V; Volk J; Newcomb CW; Yang YX; Freeman CP; Hennessy S; Kostman JR; Tebas P; Leonard MB; Localio AR
    Hepatology; 2012 Nov; 56(5):1688-98. PubMed ID: 22619086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients.
    Rivero-Juarez A; Tellez F; Castaño-Carracedo M; Merino D; Espinosa N; Santos J; Macias J; Paniagua-García M; Zapata-Lopez A; Collado A; Gómez-Vidal MA; Perez-Stachowski J; Muñoz-Medina L; Fernandez-Fuertes E; Rivero A;
    HIV Med; 2019 Jul; 20(6):359-367. PubMed ID: 31006980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.